Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of M...
Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and p...
Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Redeye comments on the reverse split and new conditions of TO12.
Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial ...
Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar eval...
FDA's final minutes confirm that Orviglance is on track for NDA submission by mid-2025.
EBITA margin above 6% No more than 1.5x Net debt/EBITDA RTM Dividend at ~30% of net profit Ambitiou...
VBG Group visar fortsatt god lönsamhet trots en utmanande marknad.
Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.
Q4 figures slightly below ABGSCe Brage reserve uplift strengthens production outlook and valuation W...
Sprint Bioscience has secured 73.9% of a proposed SEK 31.
Intäkterna för den fjärde kvartalet uppgick till 0,6 (0,9) miljoner kronor.
Redeye endorses today’s news that Acarix was named the 2025 Digital Innovation Winner by the Global ...
Fiskars transitions to SaaS-based Direct-to-Consumer (DTC) services and takes EUR 27m impairment to ...
Q4: Headline figures pre-announced last week... ...
Atria will start planning an investment programme related to the production of convenience food at t...
12% EBITA margin target looks doable... ...more uncertainty on the 8% org.
Redeye gives a short comment on the positive outcome of Elicera’s TO2 warrant program.
